Stock Analiz

RVTY vs BIO stock comparison

Revvity vs. Bio-rad Laboratories · data as of November 13, 2026

Revvity (RVTY) has a market value of about $17.2B, Bio-rad Laboratories (BIO) about $9.9B. Over their latest twelve months Revvity had revenue of $2.9B and Bio-rad Laboratories $2.6B.

On our five checks Bio-rad Laboratories scores higher: 2.2 out of 5 (weak) against 1.8 (weak).

By area, the stronger company is Bio-rad Laboratories on value; Bio-rad Laboratories on future growth; Revvity on track record; Revvity on shareholder returns.

Bio-rad Laboratories is cheaper on earnings (P/E 9.7 vs. 68.6).

Revvity leads on 14 of the compared lines and Bio-rad Laboratories on 9.

Side by side

RVTYBIO
Size and price
Market cap$17.2B$9.9B
Share price$154.39$366.36
Score
Overall score (of 5)1.82.2
Value02
Future growth13
Track record10
Financial health33
Shareholder returns43
Valuation
P/E (TTM)68.69.7
Forward P/E26.434.5
Price / free cash flow29.229.9
Price / sales5.93.8
EV / EBITDA24.792.3
PEG——
DCF value vs. price−56%−62%
Business
Revenue$2.9B$2.6B
Net income$253M$1.0B
Free cash flow$590M$329M
Net margin8.6%39.5%
Gross margin (5-yr avg.)61.8%54.2%
ROIC (5-yr avg.)4.1%2.4%
Growth
Revenue growth (1 yr)3.7%0.7%
Revenue growth (5 yrs, per year)-5.5%0.3%
EPS growth (5 yrs, per year)-20.4%-26.1%
Balance sheet and payouts
Net cash (cash minus debt)-$2.2B$301M
Dividend yield0.18%None
Shareholder yield4.9%3.0%
Analysts
Upside to average target+11%−3%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: RVTY TTM to October 4, 2026, BIO TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Revvity or Bio-rad Laboratories?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Bio-rad Laboratories scores 2.2 out of 5 and Revvity 1.8; the table shows where each one is stronger.

Is Revvity cheaper than Bio-rad Laboratories?

On trailing earnings, Bio-rad Laboratories trades at a P/E of 9.7 and Revvity at 68.6, so Bio-rad Laboratories is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Revvity or Bio-rad Laboratories?

Over five years Bio-rad Laboratories grew revenue about 0.3% a year and Revvity about -5.5% a year.

Which pays a higher dividend?

Revvity yields 0.18% and Bio-rad Laboratories nothing (no dividend).

Full Revvity analysis → Full Bio-rad Laboratories analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.